Susan R Kahn1, Andrew M Hirsch2, Arash Akaberi3, Paul Hernandez4, David R Anderson4, Philip S Wells5, Marc A Rodger5, Susan Solymoss6, Michael J Kovacs7, Lawrence Rudski2, Avi Shimony8, Carole Dennie9, Christopher Rush10, William H Geerts11, Shawn D Aaron5, John T Granton12. 1. Department of Medicine, Jewish General Hospital, Montreal, QC; Center for Clinical Epidemiology, Lady Davis Institute, Montreal, QC; Department of Medicine, McGill University, Montreal, QC. Electronic address: susan.kahn@mcgill.ca. 2. Department of Medicine, Jewish General Hospital, Montreal, QC. 3. Center for Clinical Epidemiology, Lady Davis Institute, Montreal, QC. 4. Department of Medicine, Dalhousie University, Halifax, NS. 5. Department of Medicine, University of Ottawa, Ottawa, ON. 6. Department of Medicine, McGill University, Montreal, QC. 7. Department of Medicine, Division of Hematology, Western University, London, ON. 8. Department of Cardiology, Ben Gurion University, Beer Sheva, Israel. 9. Department of Diagnostic Imaging, University of Ottawa, Ottawa, ON. 10. Department of Nuclear Medicine, Jewish General Hospital, Montreal, QC. 11. Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 12. Division of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND: We aimed to determine the frequency and predictors of exercise limitation after pulmonary embolism (PE) and to assess its association with health-related quality of life (HRQoL) and dyspnea. METHODS: One hundred patients with acute PE were recruited at five Canadian hospitals from 2010 to 2013. Cardiopulmonary exercise testing (CPET) was performed at 1 and 12 months. Quality of life (QoL), dyspnea, 6-min walk distance (6MWD), residual clot burden (perfusion scan, CT pulmonary angiography), cardiac function (echocardiography), and pulmonary function tests (PFTs) were measured during follow-up. The prespecified primary outcome was percent predicted peak oxygen uptake (Vo2 peak) < 80% at 1-year CPET. RESULTS: At 1 year, 40 of 86 patients (46.5%) had percent predicted Vo2 peak < 80% on CPET, which was associated with significantly worse generic health-related QoL (HRQoL), PE-specific HRQoL and dyspnea scores, and significantly reduced 6MWD at 1 year. Predictors of the primary outcome included male sex (relative risk [RR], 3.2; 95% CI, 1.3-8.1), age (RR, 0.98; 95% CI, 0.96-0.99 per 1-year age increase), BMI (RR 1.1; 95% CI, 1.01-1.2 per 1 kg/m2 BMI increase), and smoking history (RR, 1.8; 95% CI, 1.1-2.9), as well as percent predicted Vo2 peak < 80% on CPET at 1 month (RR, 3.8; 95% CI,1.9-7.2), and 6MWD at 1 month (RR, 0.82; 95% CI, 0.7-0.9 per 30-m increased walking distance). Baseline or residual clot burden was not associated with the primary outcome. Mean PFT and echocardiographic results (pulmonary artery pressure, right and left ventricular systolic function) at 1 year were similarly within normal limits in both patients with exercise limitations and those without such limitations. CONCLUSIONS: Almost half of patients with PE have exercise limitation at 1 year that adversely influences HRQoL, dyspnea, and walking distance. CPET or 6MWD testing at 1 month may help to identify patients with a higher risk of exercise limitation at 1 year after PE. Based on our results, we believe that the deconditioning that occurs after acute PE could underlie this exercise limitation, but we cannot exclude the fact that this may have been present before PE. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01174628; URL: www.clinicaltrials.gov.
BACKGROUND: We aimed to determine the frequency and predictors of exercise limitation after pulmonary embolism (PE) and to assess its association with health-related quality of life (HRQoL) and dyspnea. METHODS: One hundred patients with acute PE were recruited at five Canadian hospitals from 2010 to 2013. Cardiopulmonary exercise testing (CPET) was performed at 1 and 12 months. Quality of life (QoL), dyspnea, 6-min walk distance (6MWD), residual clot burden (perfusion scan, CT pulmonary angiography), cardiac function (echocardiography), and pulmonary function tests (PFTs) were measured during follow-up. The prespecified primary outcome was percent predicted peak oxygen uptake (Vo2 peak) < 80% at 1-year CPET. RESULTS: At 1 year, 40 of 86 patients (46.5%) had percent predicted Vo2 peak < 80% on CPET, which was associated with significantly worse generic health-related QoL (HRQoL), PE-specific HRQoL and dyspnea scores, and significantly reduced 6MWD at 1 year. Predictors of the primary outcome included male sex (relative risk [RR], 3.2; 95% CI, 1.3-8.1), age (RR, 0.98; 95% CI, 0.96-0.99 per 1-year age increase), BMI (RR 1.1; 95% CI, 1.01-1.2 per 1 kg/m2 BMI increase), and smoking history (RR, 1.8; 95% CI, 1.1-2.9), as well as percent predicted Vo2 peak < 80% on CPET at 1 month (RR, 3.8; 95% CI,1.9-7.2), and 6MWD at 1 month (RR, 0.82; 95% CI, 0.7-0.9 per 30-m increased walking distance). Baseline or residual clot burden was not associated with the primary outcome. Mean PFT and echocardiographic results (pulmonary artery pressure, right and left ventricular systolic function) at 1 year were similarly within normal limits in both patients with exercise limitations and those without such limitations. CONCLUSIONS: Almost half of patients with PE have exercise limitation at 1 year that adversely influences HRQoL, dyspnea, and walking distance. CPET or 6MWD testing at 1 month may help to identify patients with a higher risk of exercise limitation at 1 year after PE. Based on our results, we believe that the deconditioning that occurs after acute PE could underlie this exercise limitation, but we cannot exclude the fact that this may have been present before PE. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01174628; URL: www.clinicaltrials.gov.
Authors: K A Hagan; L B Harrington; J Kim; O Zeleznik; E B Rimm; F Grodstein; C Kabrhel Journal: J Thromb Haemost Date: 2018-06-08 Impact factor: 5.824
Authors: Rida Hasan; Maria Hanna; Song Zhang; Kendra Malone; Elizabeth Tong; Niavana Salas; Ravi Sarode; Janna Journeycake; Ayesha Zia Journal: Blood Adv Date: 2020-08-11
Authors: Rafael S Cires-Drouet; Minerva Mayorga-Carlin; Shahab Toursavadkohi; Rachel White; Emily Redding; Frederick Durham; Kathleen Dondero; Steven J Prior; John D Sorkin; Brajesh K Lal Journal: Phlebology Date: 2020-07-27 Impact factor: 1.740